BNP Paribas Financial Markets Invests $2.03 Million in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

BNP Paribas Financial Markets purchased a new position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 58,857 shares of the company’s stock, valued at approximately $2,025,000. BNP Paribas Financial Markets owned approximately 0.10% of Harmony Biosciences at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. KBC Group NV increased its holdings in shares of Harmony Biosciences by 79.9% during the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock valued at $63,000 after acquiring an additional 819 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Harmony Biosciences by 28.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company’s stock valued at $80,000 after acquiring an additional 519 shares during the last quarter. Summit Investment Advisors Inc. increased its holdings in shares of Harmony Biosciences by 34.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,987 shares of the company’s stock valued at $137,000 after acquiring an additional 1,029 shares during the last quarter. Avanza Fonder AB acquired a new position in shares of Harmony Biosciences during the 4th quarter valued at about $145,000. Finally, CIBC Private Wealth Group LLC increased its holdings in shares of Harmony Biosciences by 66.4% during the 4th quarter. CIBC Private Wealth Group LLC now owns 4,214 shares of the company’s stock valued at $146,000 after acquiring an additional 1,681 shares during the last quarter. 86.23% of the stock is owned by hedge funds and other institutional investors.

Harmony Biosciences Price Performance

Harmony Biosciences stock opened at $35.07 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The company has a market capitalization of $2.01 billion, a PE ratio of 16.62, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82. Harmony Biosciences Holdings, Inc. has a one year low of $26.47 and a one year high of $41.61. The business has a 50 day simple moving average of $31.45 and a 200 day simple moving average of $33.96.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.19. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. During the same quarter in the previous year, the company posted $0.67 EPS. The business’s revenue for the quarter was up 19.5% compared to the same quarter last year. On average, sell-side analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HRMY has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a report on Tuesday, February 11th. They set a “buy” rating and a $55.00 price objective on the stock. UBS Group lowered their target price on Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Monday, April 28th. Mizuho raised their target price on Harmony Biosciences from $44.00 to $48.00 and gave the company an “outperform” rating in a report on Thursday. Cantor Fitzgerald raised Harmony Biosciences to a “strong-buy” rating in a report on Tuesday, May 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Harmony Biosciences in a report on Tuesday, April 8th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $52.78.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.